Alembic Pharmaceuticals Limited (APLLTD) announced today that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Venetoclax Tablets, 10 mg, 50 mg, and 100 mg. This approval marks a significant milestone for Alembic, as the approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Venclexta Tablets, of AbbVie Inc. Venetoclax tablets are indicated for treating adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and, in combination with other drugs, for newly diagnosed acute myeloid leukemia (AML) in adults aged 75 or older or those with comorbidities. With this approval, Alembic may be eligible for 180 days of generic drug exclusivity. According to IQVIA, the market size for Venetoclax tablets was estimated at US $1,584 million in the United States for the twelve months ending June 2026. This approval adds to Alembic’s cumulative total of 248 ANDA approvals from the USFDA, reinforcing its position as a leader in branded generics in India.

Significance of the Approval

The USFDA approval for Venetoclax tablets is a testament to Alembic’s commitment to providing affordable and effective treatment options for various cancers. Venetoclax has shown significant efficacy in treating chronic lymphocytic leukemia and acute myeloid leukemia, offering hope to numerous patients. This approval not only expands Alembic’s generic drug portfolio but also underscores the company’s capability to deliver high-quality, cost-effective medications to the US market.

Company’s Position in the Generic Drug Market

Alembic Pharmaceuticals Limited, established in 1907, has been at the forefront of healthcare innovation. The company’s vertically integrated research and development model has enabled it to manufacture and market a wide range of generic pharmaceutical products globally. With state-of-the-art research and manufacturing facilities approved by regulatory authorities worldwide, Alembic continues to lead in the branded generics sector in India. The recent approval for Venetoclax tablets is a significant addition to its extensive list of ANDA approvals, reflecting the company’s robust pipeline and strategic growth in the generic drug market.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Alembic moves sideways over three months, with neither buyers nor sellers taking control. Thin margins at 8.9% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. Buyers show up with 1.5x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. Revenue grows at 9.5% and profits at 25.4%, and the dividend yield stands at 1.51%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Alembic Pharmaceuticals Limited.

Alembic Pharmaceuticals Limited (APLLTD) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Valganciclovir for Oral Solution, 50 mg/mL. This approval marks a significant milestone for Alembic as it continues to expand its generic drug portfolio. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Valcyte for Oral Solution 50 mg/mL of CHEPLAPHARM Arzneimittel GmbH (CHEPLAPHARM).

Valganciclovir for Oral Solution Indications

Valganciclovir for oral solution is indicated for: 1) treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS), and 2) prevention of CMV disease in kidney, heart, or kidney-pancreas transplant patients at high risk. Refer to the label for a detailed indication and usage.

Company’s Approval Milestone

With this approval, Alembic Pharmaceuticals Limited has now secured a cumulative total of 247 ANDA approvals (227 final approvals and 20 tentative approvals) from the USFDA. This achievement underscores Alembic’s commitment to providing high-quality, affordable generic pharmaceutical products to meet global healthcare needs.

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products worldwide. The company’s state-of-the-art research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Alembic moves sideways over three months, with neither buyers nor sellers taking control. Thin margins at 8.9% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. Buyers show up with 1.5x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. Revenue grows at 9.5% and profits at 25.4%, and the dividend yield stands at 1.51%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Alembic Pharmaceuticals Limited.

Alembic Pharmaceuticals Limited (Alembic) announced today that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%. This marks a significant milestone for the company, as the approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Ciprodex Otic Suspension, 0.3% / 0.1%, of Sandoz Inc. This approval will enable Alembic to offer an affordable treatment option for infections caused by susceptible microorganisms in both acute otitis media and acute otitis externa.

Market Potential

According to IQVIA, the estimated market size for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%, was US$110 million for twelve months ending June 2026. This approval further strengthens Alembic’s position in the generic pharmaceutical market, showcasing its capability to bring high-quality, cost-effective medications to patients.

Company Overview

Alembic Pharmaceuticals Limited, headquartered in India, has been at the forefront of healthcare since 1907. As a vertically integrated research and development pharmaceutical company, Alembic manufactures and markets generic pharmaceutical products globally. With state-of-the-art research and manufacturing facilities approved by regulatory authorities in many developed countries, including the USFDA, Alembic continues to lead in branded generics in India.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Alembic moves sideways over three months, with neither buyers nor sellers taking control. Thin margins at 8.9% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. Buyers show up with 1.5x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. Revenue grows at 9.5% and profits at 25.4%, and the dividend yield stands at 1.51%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Alembic Pharmaceuticals Limited.